COLORADO SPRINGS, Colo., Jan. 16, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, proudly announces plans for international observational studies and research in 2014.
Cannabis Science is a cannabinoid portfolio company. Plans announced by Cannabis Science to launch an observational clinical research study in 2014 will focus on patient driven use of cannabis and cannabis based products and the clinical outcomes of such use for a variety of medical conditions. Cannabis Science will seek additional funding partners as well as academic and clinical collaborators for this project.
Cannabis Science has been continuously conducting research into on cannabis and cannabinoids and in 2013 has also filed an application of a cannabinoid based patent and believes there is an enormous potential for the extension of its portfolio and filing of further patents.
The direction of Cannabis Science is supported by Dr. Sanjay Gupta's reversing his original position on cannabis from believing that it was harmful to supporting the use of medical cannabis. Further, the overall medical industry is moving towards accepting cannabis and cannabinoid based products as medicines. The number of cannabinoid-based products in pharmaceutical development is increasing, and Cannabis Science plans to join the ranks with its own products.
"This observational study will focus on applied cannabis based medication for a number of diseases. We will work with full authorization of the regulatory authorities and, most importantly, with the approval from patients, in order to show that Cannabis Science products are the best choice on the market," stated Prof. Robert Melamede, Ph.D., President of Cannabis Science, Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's Sarcoma.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Robert Kane, CFO & Director
SOURCE Cannabis Science, Inc.